OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	431
Lymphatic propagation of α-synuclein	429
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	325
Brain stimulation aids walking after spinal injury	324
ANA2025 marks important milestones for the ANA and NINDS	312
Global synergistic actions to improve brain health for human development	303
Reply to ‘Perils and pitfalls of near-death experience research’	296
Nociceptive action of calcitonin gene-related peptide in the trigeminovascular system	265
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	263
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	259
Genetic insights from Parkinson disease in African and African admixed populations	256
Neural cell state shifts and fate loss in ageing and age-related diseases	216
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	215
Disease-specific modifications of tau protein	196
Continuous levodopa production by an artificial enzyme	195
TREM2 mediates phagocytosis in glioblastoma	177
SEQUINS — a new initiative to address disparities in neurology	175
Nir Giladi (1955–2024)	162
Spinal muscular atrophy treatment in utero	159
Gut macrophages involved in Parkinson disease pathogenesis	150
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	148
Mitochondrial DNA instability in Huntington disease	142
The Digitized Memory Clinic	140
Imperatives and co-benefits of research into climate change and neurological disease	136
The role of the gut microbiota in multiple sclerosis	132

The impact of rare genetic variants on Alzheimer disease	131
Ultrasound lets gene therapy into the brain	128
Psychosis-causing lesions mapped to a hippocampal circuit	128
Menopause influences tau pathology	108
Brain volume is associated with cognition in MS	106
Amyloid plaques: hotspots for microglial turnover	106
Challenges of combining multimodal data in assessment of people with traumatic brain injury	104
MRI-based deep learning for TLE diagnosis	99
Gene therapy for seizures in focal cortical dysplasia	96
Neurological care for LGBT+ people	94
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	93
First trials test targeting of α-synuclein for Parkinson disease	88
The challenges of anti-tau therapeutics in Alzheimer disease	87
Author Correction: Viral pathogens increase risk of neurodegenerative disease	83
Neuroinflammation predicts cognitive decline in FTD	82
Precision neuroimmunology in multiple sclerosis — the horizon is near	82
Diversity, equity and inclusion in neurology	81
Implications of AD plasma and PET biomarker discordance	77
α-Synuclein pathology as a target in neurodegenerative diseases	77
Management of freezing of gait — mechanism-based practical recommendations	76
Parkinson disease pathology can originate in the kidney	76
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	75
Food is brain medicine — relevance and translation to neurology	74
Neurosteroids alleviate seizures in rats	73
Glymphatic dysfunction in PD clinical progression	72
A new biological classification for Parkinson disease	71
Addressing disparities in neurology by building the workforce in LMICs	70
Thalamic inflammation — a therapeutic target for brain injury?	69
Ultrasound ablation treatment for PD	69
New IDEAS about amyloid, race and dementia disparities	67
Spinal cord stimulation for the treatment of chronic pain	63
Skull bone marrow changes in multiple sclerosis	62
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	60
Coeliac disease as a model for understanding multiple sclerosis	59
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus	58
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	57
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	57
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	57
Is Alzheimer disease a disease?	56
From the prodromal stage of multiple sclerosis to disease prevention	56
The global and regional burden of diabetic peripheral neuropathy	54
Synaptic degeneration in Alzheimer disease	52
Oligomeric tau could spread through synapses in AD	50
Hypothyroidism is associated with dementia risk	49
X-chromosome variants and PD in Latin America	49
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	48
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	48
Neurofilament light chain induces neuroinflammation	46
Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	46
Neurology in 2025 — reflections from Africa	46

Peripheral nervous system immune-related adverse events due to checkpoint inhibition	45
Lorenzo’s House: shining a light on young-onset dementia	45
Global epidemiology of migraine and its implications for public health and health policy	44
Moving towards meaningful patient and public engagement	42
Risk locus for paediatric astrocytoma identified	42
The inter-relationship between delirium and dementia: the importance of delirium prevention	42
Dual function of biomolecular condensates	42
α-Synuclein seeds in amyotrophic lateral sclerosis	41
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	40
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	36
Prognostic plasma biomarkers for spinal cord injury	36
Reply to ‘Recalled experiences of death: need for empirical research without prejudice’	34
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	34
Neurology in 2025 — reflections from the USA	34
New developments in guidelines for brain death/death by neurological criteria	31
Huntington disease-like 2: insight into neurodegeneration from an African disease	30
CAR T cells offer hope in glioblastoma	30
Promoting collaboration at the brain–heart interface	29
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	29
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	28
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	28
Understanding the long-term neurological effects of SARS-CoV-2 infection	28
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	27
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	27
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	26
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	26
Origins and immunopathogenesis of autoimmune central nervous system disorders	26
BCAS1+ oligodendrocytes aid remyelination in MS	25
ALS pathogenesis linked to actin barrier collapse	25
Author Correction: The complex aetiology of cerebral palsy	24
Urogenital dysfunction in neurological diseases	23
Pathogenetic mechanisms and treatment targets in cerebral malaria	23
Pharmacological rehabilitation for stroke	21
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	21
AI aces diagnosis of chronic ataxias	21
Genome-wide analysis furthers decoding of Alzheimer disease genetics	21
AI and protein structure and function in neurological disease: relevance to disease management	20
The murky waters of sex differences in post-stroke cognitive impairment	19
The potential of low-field MRI for global dementia care	19
Molecular biomarkers for vascular cognitive impairment and dementia	19
Immune gateways bypass blood–brain barrier for drug delivery in stroke	19
Addressing disparities in the global epidemiology of stroke	18
Serum NfL as an MS biomarker	18
Effects of diet on MS onset and course	17
Clocking the age of Parkinson disease onset	17
Altered muscle cholesterol transport in ALS	17
Nusinersen treatment response markers	17
Nanoprobe for blood–brain barrier changes	16
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	15
From adaptive deep brain stimulation to adaptive circuit targeting	15
Sex and gender in neurodevelopmental conditions	15
Mechanistic insights into the interaction between epilepsy and sleep	15
Predictive tools in psychosis: what is ‘good enough’?	15
Alzheimer disease seen through the lens of sex and gender	14
Advancing multiple sclerosis management in older adults	14
Limitations of neurocentric models for near-death experiences	13
Multidimensional MRI detects astrogliosis	13
Walking the Talk for Dementia — an experience to break down barriers	13
Markers help to predict dementia with Lewy bodies	13
Alzheimer disease in Down syndrome linked to APOE	13
Shared glial pathology in HD and schizophrenia	13
Author Correction: Why functional neurological disorder is not feigning or malingering	12
Artificial intelligence in epilepsy — applications and pathways to the clinic	12
Seizure-associated changes in the Golgi apparatus	12
Advancing neurogenetics in Africa: past achievements, current developments and shaping the future	12
Psychiatric sequelae of traumatic brain injury — future directions in research	12
Advances in the therapeutic algorithm for myasthenia gravis	12
Immune mechanisms and shared immune targets in neurodegenerative diseases	12